QCG
ALDX icon

Quadrant Capital Group’s Aldeyra Therapeutics ALDX Stock Holding History

Quadrant Capital Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-185
Closed -$313 – 1286
2026
Q1 		$313 Hold
185
– – ﹤0.01% 2651
2025
Q4 		$959 Hold
185
– – ﹤0.01% 2601
2025
Q3 		$966 Buy
+185
New +$965 ﹤0.01% 2557

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Quadrant Capital Group's ALDX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 185 shares — an estimated $313 sold.

Quadrant Capital Group first reported a position in ALDX in Q3 2025 and held it in 3 quarters. The position peaked at $966 in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 185 Aldeyra Therapeutics shares in Q2 2026, an estimated $313.
  • Quadrant Capital Group first reported a position in Aldeyra Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrant Capital Group's Aldeyra Therapeutics position peaked at $966 in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.